Alumis’ (ALMS) Overweight Rating Reaffirmed at Cantor Fitzgerald

Cantor Fitzgerald reissued their overweight rating on shares of Alumis (NASDAQ:ALMS) in a research note issued to investors on Thursday,Benzinga reports.

A number of other research firms have also recently commented on ALMS. Baird R W raised Alumis to a “strong-buy” rating in a report on Thursday, October 31st. Guggenheim assumed coverage on Alumis in a report on Tuesday, July 23rd. They issued a “buy” rating and a $32.00 target price on the stock. Robert W. Baird assumed coverage on Alumis in a report on Thursday, October 31st. They issued an “outperform” rating and a $25.00 target price on the stock. Leerink Partnrs raised Alumis to a “strong-buy” rating in a report on Tuesday, July 23rd. Finally, HC Wainwright reduced their target price on Alumis from $30.00 to $26.00 and set a “buy” rating on the stock in a report on Thursday. Six research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Buy” and an average target price of $26.83.

Alumis Stock Down 2.3 %

NASDAQ:ALMS traded down $0.22 on Thursday, reaching $9.19. 154,797 shares of the company’s stock traded hands, compared to its average volume of 151,367. The stock’s 50-day moving average is $11.29. Alumis has a 12 month low of $8.23 and a 12 month high of $13.53.

Alumis (NASDAQ:ALMS) last posted its quarterly earnings results on Tuesday, August 13th. The company reported ($23.10) EPS for the quarter, missing analysts’ consensus estimates of ($1.57) by ($21.53). Sell-side analysts anticipate that Alumis will post -8 earnings per share for the current fiscal year.

Institutional Trading of Alumis

Several hedge funds and other institutional investors have recently made changes to their positions in the business. SR One Capital Management LP acquired a new stake in shares of Alumis during the 2nd quarter valued at about $26,067,000. Towerview LLC lifted its stake in Alumis by 22.6% in the 3rd quarter. Towerview LLC now owns 380,000 shares of the company’s stock worth $4,058,000 after purchasing an additional 70,000 shares in the last quarter. Millennium Management LLC purchased a new position in Alumis in the 2nd quarter worth approximately $3,376,000. Maven Securities LTD purchased a new stake in shares of Alumis during the 2nd quarter valued at approximately $332,000. Finally, Yu Fan purchased a new stake in shares of Alumis during the 2nd quarter valued at approximately $10,502,000.

About Alumis

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.